Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | PHGDH | O43175 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2069060 | 0.85 | GAA (0.74) | GAAALDH1A1KDM4EHTT | |
| SCHEMBL1346520 | 0.84 | ALDH1A1 (0.65) | GAAPHGDHALDH1A1KDM4ENPC1 | |
| SCHEMBL7012000 | 0.82 | ALDH1A1 (0.72) | GAAALDH1A1KDM4EF10NPC1 | |
| SCHEMBL1346427 | 0.82 | CYP1A2 (0.57) | GAAPHGDHCA12CA1CA2 | |
| SCHEMBL7017091 | 0.81 | MMP2 (0.49) | GAAALDH1A1KDM4EF10NPC1 | |
| SCHEMBL2070112 | 0.80 | ALDH1A1 (0.56) | GAAPHGDHALDH1A1KDM4ECA12 | |
| SCHEMBL6791925 | 0.80 | ALDH1A1 (0.57) | GAAALDH1A1KDM4ENPC1HTT | |
| SCHEMBL1347508 | 0.79 | MEN1 (0.46) | GAAPHGDHALDH1A1KDM4ECA12 | |
| SCHEMBL7010697 | 0.79 | F10 (0.47) | ALDH1A1KDM4EF10 | |
| SCHEMBL1346552 | 0.78 | CA12 (0.49) | PHGDHALDH1A1KDM4ENPC1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1302462-A1 | SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | SULT1E1, RRS1, SHH | GAA 4731/4885PHGDH 3045/4885ALDH1A1 4317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.